Chung et al. (2023) concluded that the use of SGLT2i is associated with reduced overall cancer-related mortality (HR: 0.58, p < 0.001) and reduced incidence of cancer compared with DPP-4 inhibitors (HR: 0.7, p < 0.001) [65]. The gene discussed is DPP4; the disease is cancer.